Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at 2nd Annual Boston Cannabis Conference Presented by Cowen

Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at 2nd Annual Boston Cannabis Conference Presented by Cowen

Woonsocket, RI and Toronto, ON – November 6th, 2019 – Abacus Health Products, Inc. (CSE: ABCS, OTCQX:ABAHF) (“Abacus” or the “Company”) today announced that it will participate at the 2nd Annual Boston Cannabis Conference presented by Cowen. The event will be hosted on November 11- 13th 2019 at The Intercontinental Boston.

Abacus’ CEO Perry Antelman will participate in a panel discussion on CBD alongside other leading CBD companies.  Abacus has also confirmed Cowen CEO Jeffrey Solomon will sit down for a fireside chat with Rob Gronkowski which will highlight Abacus’ recent partnership with the three-time football world champion. Abacus will be available for 1×1 meetings throughout the conference.

 

###

 

About Abacus Health Products, Inc.

 

Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

 

To learn more about Abacus, visit www.abacushp.com

 

For further information:

 

Hank Hague, Chief Financial Officer

 

Email: [email protected]

 

Or

 

Bill Mitoulas, Investor Relations

 

Email: [email protected]

 

Office: 1.416.479.9547

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *